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Chapter 1 
Capstone Report Introduction 
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Introduction 
 The CDC’s Advisory Committee on Immunization Practices (ACIP) currently 
recommends that all 11-12 year old males and females be vaccinated with the three-dose 
human papillomavirus (HPV) vaccine (CDC, 2011a; Markowitz et al., 2006).  Research 
has indicated that the vaccine is safe and effective against cervical, anal, and oral HPV 
infections; however, vaccination rates in the United States (U.S.) have remained low 
(CDC, 2013b).  National data for 2012 indicate that roughly 54% of females and 21% of 
males initiated the HPV vaccine, and only 33% of females and 7% of males completed 
the three-dose series (CDC, 2013b).  These rates are a stark contrast to vaccination rates 
for other vaccinations recommended for the same 11-12 year old age group including 
Tdap (84.6%) and meningococcal (74.0%; CDC, 2013b).     
 Because HPV related cancers are largely vaccine preventable, continued low HPV 
vaccination rates in the U.S. have prompted concern within the medical community.  
Indeed, the U.S. Department of Health and Human Services Healthy People 2020 
includes an objective to increase the number of females ages 13-15 who have received all 
three doses of the HPV vaccine to 80% (HHS, 2013).  Additionally, the President’s 
Cancer Panel (PCP) issued a report in February 2014 addressing the low vaccination rates 
and urging the President and the nation to take steps to accelerate HPV vaccine uptake 
(PCP, 2014).   
 This capstone project will present three manuscripts that explore the HPV vaccine 
and strategies to increase vaccination rates.  The first manuscript is an integrative review 
of HPV vaccine efficacy in both males and females.  It discusses studies that evaluated 
vaccine efficacy against cervical cancer, anal HPV infection in women, oral HPV 
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infection in women, and HPV infection in men.  The second manuscript analyzes a 
healthcare policy proposed in Kentucky in 2013 that would require the HPV vaccine for 
all adolescent males and females prior to sixth grade entry in the state.  Ultimately this 
policy was unsuccessful, but the introduction of healthcare policy is one proposed 
approach to increasing HPV vaccination rates.  Finally, the third manuscript is a report of 
a quality improvement project with three aims:  1) to describe primary care providers’ 
practices related to HPV vaccine recommendations, 2) to identify primary care providers’ 
facilitators and barriers to recommending the HPV vaccine, and 3) to determine the HPV 
vaccination rate among 11-12 year old patients within an urban primary care clinic.  The 
combined information gathered from these manuscripts will be used to offer evidence 
based practice recommendations for primary care providers to increase HPV vaccination 
rates within their practices.   
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Chapter 2 
 
Manuscript #1: 
 
HPV Vaccine Efficacy in Males and Females:  An Integrative Review 
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Abstract 
Purpose:  The purpose of this literature review is to describe the current research 
regarding the efficacy of human papillomavirus (HPV) vaccines for both males and 
females.  This review will investigate vaccine efficacy against cervical, anal, and oral 
HPV infection and vaccine safety. 
Data Sources:  The data was gathered from ten studies that focused on HPV vaccine 
efficacy and safety.  A literature search was conducted using CINAHL, PubMed, the 
Cochrane Database, Google Scholar, and hand searching for randomized controlled trials 
(RCTs) and systematic reviews related to HPV vaccine efficacy. 
Findings:  Short-term studies indicate that both the bivalent (protecting against HPV 16 
and 18) and quadrivalent (protecting against HPV 6, 11, 16, and 18) vaccines were 94.5-
100% effective against cervical lesions caused by their respective HPV types in women.  
Additionally, the bivalent vaccine has been shown to be 83.6% effective against anal 
HPV 16/18 infection in women, and 93.3% effective against oral HPV 16/18 infection in 
women.  In men, the quadrivalent vaccine was 90.4% effective against genital lesions and 
77.5% effective against anal intraepithelial neoplasias caused by HPV types 6, 11, 16, or 
18.  The most commonly reported adverse event related to the vaccine is pain at the 
injection site, and the number of serious adverse events was similar in the vaccine and 
control groups in all studies that reported on vaccine safety.   
Implications for Practice:  Providers should continue to follow the Advisory Committee 
for Immunization Practices (ACIP) recommendations for HPV vaccination of males with 
the quadrivalent vaccine and females with either the bivalent or quadrivalent vaccine, as 
studies continue to support vaccine efficacy and safety. 
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HPV Vaccine Efficacy in Males and Females:  An Integrative Review 
Background and Significance 
 Human papillomavirus (HPV) causes a significant disease burden for men and 
women worldwide.  By age 50, 80% of sexually active women and 60-70% of sexually 
active men will have been infected with genital HPV at some point in their lifetime 
(Garnock-Jones & Giuliano, 2011).  There are approximately 14 million new HPV 
infections annually in the United States, making it the most common sexually transmitted 
infection (CDC, 2013a).   The incidence of infection is highest between ages 15-24 for 
both men and women (Fernandez, Allen, Mistry, & Kahn, 2010), with nearly half of the 
new infections in the U.S. occurring in this age group (CDC, 2013a).  HPV is spread via 
skin to skin contact; penetrative sexual intercourse is not necessary for transmission 
(Fernandez et al., 2010).  Currently, 130 types of HPV have been discovered, while 30-40 
types are known to infect the anogenital tract (Haupt & Sings, 2011).  Of these, there are 
15 types that are oncogenic, or cancer causing (De Carvalho et al., 2010).  Nationally, the 
overall prevalence of infection with these high-risk HPV types is 23% in men and women 
ages 14-65 (CDC, 2012a).  HPV is known to cause genital warts, respiratory 
papillomatosis, and cervical, vulvar, vaginal, penile, anal, and orophayngeal cancers 
(CDC, 2010b; CDC, 2011a; Markowitz et al., 2007).    
 Healthcare providers and patients are increasingly aware of the link between HPV 
and cervical cancer.  HPV DNA is found in 99.7% of cervical cancers (Garnock-Jones & 
Giuliano, 2011), with 70% of those caused by HPV 16 or 18 (Beibei, Kumar, 
Castellsague, & Guiliano, 2011).  Worldwide, cervical cancer is still the second most 
common cancer affecting women (De Carvalho et al., 2010).  Approximately $1.5 billion 
 
 
6 
 
was spent on cervical cancer treatment in the U.S. in 2010.  The net cost for the initial 
care of cervical cancer in 2010 was $54,209 for women under 65 years old (Mariotto, 
Yabroff, Shao, Feuer, & Brown, 2011).  Additionally, there are an estimated 10 million 
cases of cervical intraepithelial neoplasias (CIN) II or III worldwide annually (The Future 
I/II Study Group, 2010), which can develop into cervical cancer if not treated.  However, 
treating high-grade CIN is costly and can lead to complications, including problems with 
fertility. 
 While anal and oropharyngeal cancers are less common than cervical cancer, their 
incidence is on the rise (Chaturvedi et al., 2011; Kreimer et al., 2011).  It has been 
estimated that 70% of oropharyngeal cancers in the U.S. are now associated with HPV 
infection (Herrero et al., 2013).  Oropharyngeal cancer occurs three times more often in 
men than women, and is primarily caused by HPV 16 (CDC, 2013b).  Rates of anal 
cancer are increasing in both women and men (Palefsky et al., 2011), although it is most 
common in men who have sex with men (Kreimer et al., 2011).  Similar to cervical 
cancer, anal cancers are primarily caused by HPV types 16 or 18 (Palefsky et al., 2011). 
 HPV is also responsible for anogenital warts.  Annually, approximately 30 million 
men and women develop low-grade CIN or anogenital warts worldwide (The Future I/II 
Study Group, 2010), with an excess of 500,000 new cases of anogenital warts yearly in 
the U.S. (Garnock-Jones & Giuliano, 2011).  Approximately 90% of anogenital warts are 
caused by HPV 6 or 11 (CDC, 2012b).  While anogenital warts are not directly associated 
with cancer, there are related psychological burdens and costs of treatment (Giuliano et 
al., 2011). 
 A quadrivalent HPV vaccine (HPV4) that protects against HPV types 6, 11, 16, 
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and 18 was developed and approved by the U.S. Food and Drug Administration (FDA) in 
2006.   Later that same year, recommendations for the administration of the vaccine to 
females ages 9-26 were released by the CDC’s Advisory Committee on Immunization 
Practices [ACIP] (Markowitz et al., 2007).  The quadrivalent vaccine is now approved for 
use in 121 countries (Haupt & Sings, 2011).   In 2009, a bivalent vaccine (HPV2) that 
protects against oncogenic HPV types 16 and 18 was introduced, and the ACIP released 
recommendations regarding its administration to females ages 9-26 (CDC, 2010).  In 
2011, the ACIP updated their recommendations again to include vaccination of males 
ages 9-21 (and up to age 26 for special populations, including men who have sex with 
men) with the quadrivalent (HPV4) vaccine (CDC, 2011a).  Both the quadrivalent and 
bivalent vaccines are a three-dose series.  The ACIP recommends the routine vaccination 
of 11-12 year old females with either the bivalent or quadrivalent vaccine, and the routine 
vaccination of males ages 11-12 with the quadrivalent vaccine (CDC, 2010a; CDC, 
2011a; Markowitz et al., 2006).   
Purpose 
 The purpose of this critical review of the literature is to describe efficacy and 
safety of the HPV vaccine for males and females.  Additionally, recommendations will be 
offered to guide practice regarding administration of the HPV vaccine to patients.  While 
the vaccine has had several years of research in women for the prevention of CIN and 
cervical cancer, newer research has been conducted to determine its efficacy in males, its 
efficacy in females against anal and oral HPV infection, and longer term efficacy against 
CIN and cervical cancer.   
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Methods 
 The literature search for this review was conducted using several databases 
including CINAHL, PubMed, the Cochrane Library, and Google Scholar.  Hand 
searching was also employed.  Search terms included HPV vaccine efficacy, quadrivalent 
HPV vaccine efficacy, bivalent HPV vaccine efficacy, human papillomavirus vaccine 
efficacy, HPV vaccine efficacy and men, HPV vaccine randomized controlled trials, and 
HPV vaccine systematic reviews.  Initially, articles were searched from 2006, the original 
date of licensure of the quadrivalent vaccine for use in females.  However, this search 
yielded many duplicate articles, and several of the randomized controlled trials had 
concluded more recent study endpoints.  Additionally, several new studies have been 
conducted since 2010 that investigated vaccine efficacy in men, and against oral and anal 
HPV infections.  Articles were included if they focused on vaccine efficacy of either the 
bivalent or quadrivalent vaccine in women, men, or both, ages 9-26.  Studies were 
excluded if they were conducted on patients older than 26 and/or were not either a 
randomized controlled trials or a systematic reviews of randomized controlled trials.  
Duplicate studies were also eliminated.  Twenty-two studies published since 2010 were 
identified, and 10 met the final criteria for review, which was current research examining 
the efficacy of HPV vaccines for males and females against cervical, anal, and/or oral 
HPV infections.   
 Findings 
Women:  Cervical Lesions 
 The majority of studies reviewed focused on vaccine efficacy related to 
anogenital warts, cervical intraepithelial neoplasia (CIN), and/or cervical cancer in 
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women.  While most studies focused on either the bivalent or quadrivalent vaccine, one 
systematic review combined studies of the monovalent (for HPV 16), the bivalent, and 
the quadrivalent vaccines and found that in the per protocol population (PPP), all vaccine 
types were highly effective against CIN 1+ (Beibei et al, 2011).  Also, while long-term 
data showing vaccine efficacy for greater than 5 years is not yet available, both the 
bivalent (Lehtinen et al., 2012) and the quadrivalent vaccines (The Future I/II Study 
Group, 2010) have been found very efficacious against their respective HPV types up to 
four years after  initial vaccination.  Another smaller study found the bivalent vaccine 
highly effective for up to 7.3 years (De Carvalho et al., 2010).  Other, shorter term studies 
of the bivalent and quadrivalent vaccines found them effective against genital lesions, 
CIN, and cervical cancer associated with vaccine HPV types (Szarewski et al., 2012; 
Yoshikawa et al., 2013).  In summary, both the bivalent and quadrivalent vaccines have 
demonstrated high efficacy against CIN and cervical cancer in women.   
Women:  Anal HPV Infection 
 Although anal cancer is uncommon in women, it is on the rise in both sexes.  
Most anal cancers can be attributed to HPV types 16 or 18 (Kreimer et al., 2011).  Only 
one study specifically investigated the efficacy of the bivalent vaccine against anal HPV 
16/18 infection in women.  In women who were negative for both HPV 16 and 18 at the 
start of the study, the vaccine showed 83.6% efficacy.   This was measured one time, four 
years after the initial vaccination, and was similar to the efficacy of the vaccine against 
cervical HPV 16 and 18 (Kreimer et al., 2011).    
Women:  Oral HPV Infection  
 While it is known that many orophayngeal cancers are caused by oral HPV 
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infection, research has been lacking to determine vaccine efficacy against oral HPV.  In 
July 2013, Herrero et al. reported findings on the efficacy of the bivalent HPV vaccine 
against oral infections with HPV 16 and 18.  This randomized controlled trial of 5834 
women ages 18-25 provided some of the first data available regarding HPV vaccine 
efficacy against oral HPV.  The women in the study were given either the bivalent HPV 
vaccine or a hepatitis A vaccine as a control.  An oral specimen was collected once, at the 
study endpoint after 4 years.  At that time, they were tested for multiple types of HPV, 
including HPV 16 and 18 (Herrero et al., 2013).  The study found the vaccine to be 
93.3% effective against oral infection with HPV 16 and 18. Oral HPV 16/18 was detected 
in one participant in the vaccine group compared to 15 HPV 16/18 infections detected in 
the control group (Herrero et al., 2013).  These findings show promise that the 
implementation of the HPV vaccine can reduce the incidence of oral HPV infection and 
consequently orophayngeal cancer.   
Men 
 Many of the vaccine efficacy studies have been focused on cervical cancer in 
women; however, men are also affected by HPV infection.  The rate of HPV infection 
among males is similar to that of the female population.  In addition to genital warts, men 
are also susceptible to penile, anal, and oropharyngeal cancers associated with HPV 
infection (Giuliano et al., 2011).  Two studies reviewed examined the male population 
and focused on the efficacy of the quadrivalent vaccine against HPV infection in males 
(Giuliano et al., 2011), and more specifically against anal intraepithelial neoplasia caused 
by HPV 6, 11, 16, or 18 (Palefsky et al., 2011).  The outcomes of these studies support 
the continuation of routine vaccination of males for the primary prevention of HPV 
 
 
11 
 
infection.  In the per protocol groups, the vaccine was 90.4% effective against any lesions 
caused by HPV 6, 11, 16, or 18; 85.6% effective against persistent HPV infection with 
these types (Giuliano et al., 2011); and 77.5% effective against anal intraepithelial 
neoplasias (Palefsky et al., 2011).   
Vaccine Safety  
 Of the six studies that looked at vaccine safety, all concluded that the HPV 
vaccine has a favorable safety profile.  The most commonly reported adverse events were 
pain at the injection site (Beibei, Kumar, Castellsague, & Giuliano, 2011; Giuliano et al., 
2011; Yoshikawa, Ebihara, Tanaka, & Noda, 2013), vaccine site reaction (Palefsky et al., 
2011), and headache (Beibei, et al., 2011; Yoshikawa, et al., 2013).  Two studies found 
that pain at the injection site was more commonly reported in the vaccine group than the 
control group (Giuliano et al., 2011; Yoshikawa, et al., 2013).  All studies found the risk 
of serious adverse events to be similar in the vaccine and control groups (Beibei, et al., 
2011; De Carvalho et al., 2010; Giuliano et al., 2011; Lehtinen et al., 2012; Palefsky et 
al., 2011; Yoshikawa, et al., 2013).   
 Table 1 
Source Sample Method  Purpose Findings 
Beibei et al. 
(2011) 
7 RCTs Systematic 
Review 
To determine 
efficacy of the 
monovalent, 
bivalent, and 
quadrivalent 
HPV vaccines 
against 
cervical HPV 
infection in 
women, and 
to explore 
vaccine safety. 
Efficacy:  Studies 
showed reduction 
of CIN 1+ and CIN 
2+ caused by HPV 
16 and 18 and 
persistent (> 6 
mo) HPV infection 
with 16/18 in 
both PPP and ITT 
groups.   
Safety:  AE did 
not differ 
significantly in 
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vaccine and 
control groups 
De Carvalho et 
al.  
(2010) 
433 women  RCT To verify long-
term efficacy 
(up to 7.3 
years after 
vaccination) of 
the bivalent 
HPV vaccine in 
young adult 
women. 
Efficacy:  Vaccine 
efficacy was high 
(94.5%) in the 
vaccine group up 
to 7.3 years post 
vaccination. 
Safety:  Safety 
profiles were 
comparable in 
the vaccine and 
placebo groups. 
The Future I/II 
Study Group 
(2010) 
17,622 women 2 RCTs (Future I 
and Future II) 
To determine 
quadrivalent 
vaccine 
efficacy 
against low 
grade cervical, 
vulvar, and 
vaginal 
intraepithelial 
neoplasias 
and 
condyloma 
acuminate. 
Efficacy:  Efficacy 
against lesions 
caused by HPV 6, 
11, 16, 18 were 
96% for CIN 1, 
100% for vulvar 
and vaginal 
intraepithelial 
neoplasia grade 
1, 99% for 
condyloma over 
42 months.   
Safety:  Not 
addressed in this 
report. 
Giuliano et al. 
(2011) 
4065 males RCT To evaluate 
the efficacy of 
the 
quadrivalent 
HPV vaccine 
against genital 
lesions caused 
by HPV 6, 11, 
16, and 18 in 
boys and men 
Efficacy:  Efficacy 
in PPP against 
HPV 6, 11, 16, 18 
lesions was 
90.4%.  Efficacy in 
ITT for HPV 6, 11, 
16, 18 lesions was 
65.5%.   
Safety:  Most 
common AE was 
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ages 16 to 26. pain at the 
injection site with 
both vaccine and 
placebo.   No 
serious AE were 
related to 
vaccination. 
Herrero et al. 
(2013) 
7466 women RCT To determine 
efficacy of 
bivalent HPV 
vaccine 
against oral 
HPV infection 
in women. 
Efficacy:  The 
vaccine was 
93.3% effective 
against oral 
infection with 
HPV 16 and/or 
18. 
Safety:  Not 
addressed in this 
report. 
Kreimer et al. 
(2011) 
4210 women RCT To evaluate 
the efficacy of 
the bivalent 
HPV vaccine 
against anal 
infection with 
HPV 16/18 in 
women ages 
18-25. 
Efficacy:   Efficacy 
against anal 
infection with 
HPV 16/18 was 
62% measured 4 
years post-
vaccination.  
Efficacy in the 
restricted cohort 
(1989 women 
who tested neg 
for HPV 16/18 at 
the start of the 
study) was 83.6%.  
Safety:  Not 
addressed in this 
report. 
Lehtinen et al. 
(2012) 
TVC group:  
vaccine=9319 
women, 
control=9325 
women 
TVC naïve group: 
vaccine=5824 
women, 
control=5820 
women 
RCT To establish 
vaccine 
efficacy of the 
bivalent HPV 
vaccine 
against grade 
3 or greater 
CIN caused by 
HPV 16/18. 
Efficacy:   Four 
years after 
vaccination, 
efficacy against 
CIN 3+ caused by 
HPV 16/18 was 
100% in TVC 
naïve group, and 
45.7% in the TVC.  
Efficacy against 
AIS was 100% in 
TVC naïve and 
76.9% in TVC. 
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Safety:  The 
number of 
women reporting 
AE were similar in 
vaccine and 
control groups. 
Palefsky et al. 
(2011) 
602 males RCT To verify the 
efficacy of the 
quadrivalent 
HPV vaccine 
against anal 
intraepithelial 
neoplasm in 
men who have 
sex with men, 
ages 16-26. 
Efficacy:  Against 
HPV 6, 11, 16, 18 
associated anal 
intraepithelial 
neoplasia was 
50.3% in ITT and 
77.5% in PPP.   
Safety:  No 
serious AE 
reported in this 
study. 
Szarewski et 
al. (2012) 
18,644 women RCT To determine 
the efficacy of 
the bivalent 
HPV vaccine 
against HPV 
16/18 
infection in 
women ages 
15-25 without 
prior exposure 
to HPV 16/18 
infection. 
Efficacy:  The 
vaccine was 
efficacious 
against HPV 
16/18 in women 
who were HPV 
16/18 DNA 
negative and 
seronegative and 
women who were 
HPV 16/18 DNA 
negative but had 
serological 
evidence of 
previous HPV 
16/18 infection.  
If women were 
HPV DNA positive 
for one type, the 
vaccine was still 
effective against 
the other type.   
Safety:  Not 
addressed in this 
report. 
Yoshikawa et 
al. (2013) 
Vaccine=509 
women 
Placebo=512 
women 
RCT To establish 
the efficacy of 
the 
quadrivalent 
HPV vaccine 
Efficacy:  
Infection with 
HPV 6, 11, 16, 18 
reduced by 87.6% 
in vaccine group.   
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against HPV 6, 
11, 16, & 18 in 
Japanese 
women ages 
18-26. 
 
 
Safety:   Pain and 
headache most 
common AE.  No 
serious AE related 
to vaccination. 
      
Discussion 
Critique of Studies 
 This review of the current literature investigating safety and efficacy of the 
bivalent and quadrivalent HPV vaccines for males and females demonstrates that both 
vaccines are safe and effective.   This paper adds to the body of evidence by providing an 
updated review of the latest research related to HPV vaccine efficacy and safety 
regarding cervical lesions in women and genital lesions in men, as well as new research 
exploring vaccine efficacy against anal and oral HPV infections.  Additionally, it reports 
some longer-term data, including vaccine efficacy of the quadrivalent vaccine against 
CIN 1, vulvar and vaginal intraepithelial neoplasias grade 1, and condyloma up to 42 
months and efficacy of the bivalent vaccine in women up to 7.3 years (De Carvalho et al., 
2010; The Future I/II Study Group, 2010).  
 While efficacy of the HPV vaccine against cervical lesions in women (particularly 
those caused by HPV 16 or 18) is high, studies examining vaccine efficacy and safety for 
longer than five years are still in progress.  Additionally, there are many areas where 
research is only in the beginning stages.  Routine vaccination with the quadrivalent 
vaccine has only been recommended for males since 2011, and the majority of research is 
focused on genital and anal lesions.  Investigations are still in progress to evaluate its 
effectiveness against penile, anal, and oropharyngeal cancers in men.  Furthermore, new 
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studies support that the vaccine can prevent anal and oral HPV infection in women, but 
additional research is needed in this area.   
   Emerging evidence has the potential to change current practice.  Recent studies 
suggest that two doses of the vaccine are possibly as effective as the traditional three-
dose series (Kreimer et al., 2011b; Romanowski et al., 2011).  Similarly, research has 
been conducted to determine vaccine efficacy against non-vaccine HPV types (Wheeler 
et al., 2012) and the effect of vaccinating women who are known to have HPV related 
cervical and vulvar disease (Joura et al., 2012).  Lastly, despite lower than desired 
vaccination rates in the United States, the incidence of HPV in females ages 14-19 with 
HPV 6, 11, 16, and 18 has decreased by 56% since the implementation of routine 
vaccination (Markowitz et al., 2013).  These are areas for further research, but have the 
potential to alter vaccine recommendations.     
 Limitations in these studies include potential conflicts of interest.  For example, 
several of the larger studies in this review were funded by pharmaceutical companies and 
the researchers were employed by the pharmaceutical companies (The Future I/II Study 
Group, 2010; Lehitenen et al., 2012; Palefsky et al., 2011; Szarewski et al., 2011).  While 
the studies were well-conducted, with large samples sizes in various sites (including 
North America, Latin America, Europe, and Asia), their funding represents potential bias.  
Other limitations include the smaller sample sizes of some studies.  While most were 
large, multi-site studies, a few had a sample size fewer than 1000 (De Carvalho et al., 
2010; Palefsky et al., 2010), or were conducted at only one site (De Carvalho et al., 2010; 
Herrero et al., 2013; Kreimer et al., 2011; Yoshikawa et al., 2013).  Lastly, the fact that 
the majority of research is still concentrated on vaccine efficacy in women against CIN or 
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cervical cancer represents a potential limitation.  Only two of the included studies 
evaluated HPV infection in men (Giuliano et al., 2011; Palefsky et al., 2011).  Research 
in other areas, including vaccine efficacy in men and vaccine efficacy against anal and 
oral HPV infections, is lacking.  
Recommendations for Practice 
 Providers should know that, to date, both the bivalent and quadrivalent vaccines 
have shown high efficacy against their respective HPV types.  Additionally, in nearly all 
studies reviewed, reported adverse events were similar in the vaccine and control groups.  
Providers should continue to follow the ACIP recommendations for routine and catch-up 
administration to both male and female patients.  The quadrivalent vaccine is 
recommended for males, but it is not specified whether the bivalent or quadrivalent 
vaccine is preferable for females and thus the decision is left up to providers.  A 
compelling rationale for recommending the quadrivalent vaccine is that it also protects 
against anogenital warts caused by HPV types 6 and 11.  Additionally, it is important for 
providers to note their patients’ sexual history, as in some cases this may affect 
vaccination (for example, ACIP recommends vaccination up to 26 years old in men who 
have sex with men).   
 Given the decline in HPV 6, 11, 16, and 18 infections in adolescent girls since the 
implementation of vaccination, there is promise that continued vaccination could greatly 
reduce HPV infection and therefore lessen the incidence of associated cancers.  Two of 
the Healthy People 2020 objectives are to reduce the number of females with HPV 6, 11, 
16, and 18 infections, and to increase the number of females ages 13-15 who have 
received 3 doses of the HPV vaccine to 80% (HHS, 2013).  Potential recommendations to 
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improve vaccination rates include strong provider recommendation to patients, patient 
(and parent) education, and focusing on health policy that would mandate the vaccine for 
adolescents entering the sixth grade.         
Conclusion 
 Short-term data supports the efficacy and safety of the HPV vaccine, but long-
term data is yet to be determined.  Recent research has shown promise that the vaccine is 
effective in women for the prevention of cervical, oral, and anal HPV infections and in 
men for the prevention of genital lesions and anal HPV infections.  Since infection with 
oncogenic HPV types has been linked to cervical, vaginal, penile, anal, and orophayngeal 
cancers, a reduction in high-risk HPV infections should correlate with a reduction in 
associated cancers.  Additionally, research continues to demonstrate a positive safety 
profile for the vaccines.  Providers should continue to recommend the HPV vaccine to 
male and female patients per the ACIP recommendations as a primary prevention method 
for the reduction of HPV infection.  If vaccination rates can meet the Healthy People 
2020 objectives, morbidity, mortality, and healthcare costs associated with HPV infection 
could be greatly reduced. 
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Abstract 
 Infection with certain strains of human papillomavirus (HPV) has been associated 
with the development of cervical, vulvar, vaginal, penile, anal, and orophayngeal cancers.  
Both the bivalent and quadrivalent HPV vaccines protect against these oncogenic strains.  
Despite an ACIP recommendation that all 11-12 year old males and females should be 
routinely vaccinated against HPV in the United States, initiation and completion of the 
three-dose series are low.  One proposed intervention to increase vaccination rates is to 
introduce policy that requires HPV vaccination for school entry.  Kentucky legislators 
introduced House Bill 358 during the 2013 session that would require the vaccine for all 
males and females in the state prior to entering sixth grade.  This paper will discuss the 
social, financial, and political implications of the proposed bill, as well as alternative 
measures to increase HPV vaccination rates. 
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Policy Analysis:  Requiring the HPV Vaccine for Adolescents in Kentucky 
 The Center for Disease Control and Prevention’s (CDC) Advisory Committee on 
Immunization Practices (ACIP) in 2006 released recommendations to routinely vaccinate 
11-12 year old females (Markowitz et al., 2007), and in 2011 that 11-12 year old males 
be vaccinated (CDC, 2011a) with a three-dose human papillomavirus (HPV) vaccine.  
The bivalent vaccine (HPV2) that protects against types 16 and 18 is recommended for 
use in females; the quadrivalent vaccine (HPV4) that protects against HPV types 6, 11, 
16, and 18 is recommended for use in males and females.  However, vaccination rates 
have remained low.  In 2012, only 33.4% of adolescent females and 6.4% of adolescent 
males had completed the three-dose vaccine series (CDC, 2013d).  Implementing policy 
that would require the HPV vaccine for school entry is one proposed solution to low 
vaccination rates.  In 2013, Kentucky legislators proposed House Bill 358 that would 
require the HPV vaccine for both males and females prior to sixth grade entry.  The bill 
passed the Kentucky House of Representatives, but it was ultimately unsuccessful after 
being stalled in Senate committee.  This paper will explore the stakeholders that are 
involved and affected by a vaccine mandate, the factors that influence the development 
and acceptance of a bill, and possible alternative solutions that would facilitate an 
increase in HPV vaccination rates. 
Background and Significance 
  Human papillomavirus is a sexually transmitted disease that is extremely 
widespread.  It is estimated that 75% of sexually active people will become infected 
between the ages of 15 and 50 (La Torre, de Waure, Chiaradia, Mannocci, & Ricciardi, 
2007).  According to estimates from the CDC (2013a), there are more than 14 million 
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new infections yearly, and 79 million active infections in the United States currently.  
This makes it by far the most prevalent sexually transmitted infection (STI) in the U.S.  
Incidence of infection peaks between ages 15-24 for both men and women (Fernandez, 
Allen, Mistry, & Kahn, 2010).  Approximately 90% of HPV infections are cleared by the 
body’s immune system within one to two years.  However, infection with high-risk types 
can lead to cancerous changes and is linked to the development of cervical, vulvar, 
vaginal, penile, anal, and oropharyngeal cancers (CDC, 2011a; Markowitz et al., 2007).   
 HPV DNA was discovered in cervical cancer cells approximately 30 years ago.  It 
was later determined that over 99% of cervical cancers are caused by oncogenic strains of 
HPV; 70% of these are caused by HPV 16 and 18 (HHS, 2012).  While cervical cancer 
rates have declined in the past 50 years due to the implementation of routine screening, 
the CDC estimates that in 2010, 11,818 women were diagnosed with and 3,939 women 
died from cervical cancer in the United States (CDC, 2012c).  Kentucky is one of the 
twelve states with the highest rates of cervical cancer with an incidence of 8.1-11.2 per 
100,000 (CDC, 2012d).      
 Evidence supports a strong link between HPV infection and both oropharyngeal 
and anal cancers.  Approximately 95% of anal cancers (CDC, 2013e) and nearly 70% of 
newly diagnosed oropharyngeal cancers in the U.S. are caused by human papillomavirus 
(Herrero et al., 2013).   While HPV-related anal cancer is most common in men who have 
sex with men (Kreimer et al., 2011), the incidence of both oropharyngeal and anal 
cancers are on the rise in men and women (Herrero et al., 2013; Palefsky et al., 2011).  
Similar to cervical cancer, HPV related anal cancers are primarily caused by oncogenic 
HPV types 16 and 18 (Palefsky et al., 2011), while oral cancers are largely caused by 
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HPV 16 (Herrero et al., 2013).  Approximately 1 % of the U.S. population is infected 
with oral HPV 16, and men are three times more likely than women to be infected with 
oral HPV (CDC, 2013b).          
 HPV is also responsible for anogenital warts.  Annually, approximately 30 million 
men and women worldwide develop low-grade intraepithelial neoplasias and/or 
anogenital warts (The Future I/II Study Group, 2010), with an excess of 500,000 new 
cases of anogenital warts yearly in the U.S. (Garnock-Jones & Giuliano, 2011).  
Approximately 90% of anogenital warts are caused by HPV 6 or 11.  Conjunctival, nasal, 
oral, and laryngeal warts can also be caused by HPV 6 or 11 (CDC, 2012b).  While these 
lesions are not directly associated with cancer, there are related psychological burdens 
and costs of treatment (Giuliano et al., 2011). 
  In 2006, the United States Food and Drug Administration (FDA) approved the 
three-dose quadrivalent vaccine (HPV4) that protects against HPV types 6, 11, 16, and 
18.  In June 2006, the ACIP released recommendations regarding the administration of 
the vaccine to females (Markowitz et al., 2007).  This included recommendations to 
vaccinate females ages 9-26, with routine vaccination at ages 11-12.  Additionally, a 
bivalent vaccine (HPV2) was introduced in 2009 that protects against HPV types 16 and 
18 (CDC, 2010a).  In 2011, the ACIP updated their recommendations again to include the 
routine vaccination of males ages 11-12, and all males ages 9-21 (and up to age 26 for 
special populations including men who have sex with men and those who are 
immunocompromised) with the quadrivalent vaccine (CDC, 2011a).   
 While long-term studies are still in progress, the HPV vaccines have had positive 
reports for safety and efficacy to date (Beibei, Kumar, Castellague, & Giuliano, 2011; De 
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Carvalho et al., 2010; The Future I/II Study Group; Giuliano et al., 2011; Herrero et al., 
2013; Palefsky et al., 2011; Yoshikawa, Ebihara, Tanaka, & Noda, et al., 2013) .  Studies 
have suggested that the vaccine is highly effective at preventing cervical intraepithelial 
neoplasias (CIN) grades 1 and 2 caused by HPV 16 and 18 (Beibei, et al., 2011) and 
lesions caused by HPV 6, 11, 16, and 18 in both women (The Future I/II Study Group, 
2010; Yoshikawa, et al., 2013) and men (Giuliano et al., 2011).  The vaccine has shown 
high efficacy for up to 7.3 years post vaccination (De Carvalho et al, 2010).  
Additionally, research suggests that the vaccine is effective against oral (Herrero et al., 
2013) and anal HPV infections (Kreimer et al., 2011; Palefsky et al., 2011).  The vaccine 
also has a favorable safety profile with the most common adverse events being pain at the 
injection site (Beibei, et al., 2011; Giuliano et al., 2011; Yoshikawa, et al., 2013), vaccine 
site reaction (Palefsky et al., 2011), and headache (Beibei, et al., 2011; Yoshikawa, et al., 
2013).  Additionally, the CDC maintains that the vaccine is safe, effective, and long-
lasting according to study results thus far, with nearly 46 million doses given in the U.S. 
as of June 2012 (CDC, 2012h). 
 Statement of Problem 
 Despite evidence of both safety and efficacy, HPV vaccination rates in the U.S. 
remain low (CDC 2013d; Markowitz et al, 2007).  The 2007 National Immunization 
Survey-Adult (NIS-Adult) showed that a few months after initiation of the ACIP 
recommendations, although patient knowledge of HPV infection was high, only 10% of 
women 18-26 initiated the vaccine series (Jain et al., 2009).  By 2012, 53.8% of 
adolescent females ages 13-17 in the U.S. had received the initial dose of the HPV 
vaccine, and 33.4% had completed the three-dose series.  In Kentucky in 2012, 51.2% of 
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adolescent females had initiated the HPV vaccine series, and 34.9% had completed the 
three-dose series (CDC, 2013d).  This remains significantly lower than the compliance 
rate of other immunizations initiated during the same time period including 
meningococcal (70%) and Tdap (85%; CDC, 2012g).  National rates of HPV vaccination 
among females actually decreased slightly from 2011 to 2012 (CDC, 2013d).  One of the 
Healthy People 2020 objectives includes increasing the number of females ages 13-15 
who have completed the three-dose HPV vaccine series to 80% (HHS, 2013).  In order to 
reach this goal, providers will have to educate patients and their families, and strongly 
advocate for vaccination of all adolescents. 
 One proposed way to increase HPV vaccination rates is to introduce policy that 
mandates vaccination of all adolescents prior to sixth grade entry.  There is currently no 
federal law that dictates vaccinations; each state has different laws regarding which 
vaccines are required for school entry.  In nearly every legislative session since 2006, 
Kentucky has had proposed legislation that would require the HPV vaccine for students 
entering the sixth grade.  In the 2013 session, lawmakers proposed HB 358, a bill that 
would mandate the HPV vaccine for all adolescents entering sixth grade in Kentucky.  
While the legislation passed the House, it was stalled in Senate committee.   
 Kentucky is not the only state that has proposed legislation to require HPV 
vaccination.  Virginia and Washington D.C. have passed bills mandating that girls 
entering sixth grade receive the HPV vaccine.  Both pieces of legislature provided an ‘opt 
out’ for parents who do not desire to vaccinate their daughters.  The governor of Texas 
similarly mandated that girls entering sixth grade would be required to receive the 
vaccine, with an opportunity for parents to opt out.  This mandate was eventually 
 
 
26 
 
overruled by the Texas legislature (Chen, 2012).  Similar to Kentucky, New York and 
Virginia proposed unsuccessful legislation in 2013-2014 that would mandate the vaccine 
for males and females entering sixth grade.  Other states have proposed comparable 
legislation in previous years without success (NCSL, 2013).   
Conceptual Framework 
 The use of a guiding framework when introducing legislative agenda is important 
to increase the chance of success.  John Kingdon (2003) describes three processes, or 
“streams” that are involved when setting legislative agendas.  These processes are 
problems, policies, and politics.  Problems are the issues that are either brought to the 
attention of politicians by discussion with someone within the government, or by looking 
at different indicators that politicians use to monitor incidents and occurrences.  Some 
examples of monitoring are monetary (i.e., examining expenditures and budgets) and 
surveys (can be conducted by governmental or non-governmental groups, and sometimes 
required by a statute).  An issue may be identified as a problem, but may eventually fade 
from the agenda if appropriate action is not taken.  Policies describes the process of 
creating policy proposals.  There are many specialists in and around the government who 
are involved in the formation of policy.  Depending on the issue, the group of specialists 
involved in writing a proposal can vary widely and may include academics, researchers, 
and others close to the topic.  Again, some policy proposals move on to develop 
legislation while others do not.  Finally, politics depicts the overall political mood and 
sentiments of the public.  This stream functions independently of the other two, yet can 
have a strong impact on the agenda (Kingdon, 2003). 
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 The problem in Kentucky (as in the rest of the United States) is that HPV vaccine 
completion rates are subpar, and far below the Healthy People 2020 goal for adolescent 
females of 80%.  Data from the National Immunization Survey Teen (NIS-Teen) 2012 
can be used to support the need for action (CDC, 2013d).  This could be considered an 
indicator of a national problem.  In response to this problem, a proposal, or HB 358 
(2013), was created.  Kentucky had proposed similar bills in the past; the main difference 
with HB 358 is that it mandates vaccination of both male and female adolescents.  
However, due to politics, the bill was stalled in Senate committee and did not pass.  The 
HPV vaccine is not widely accepted by the general public, and this undoubtedly affected 
some politicians’ decisions regarding a vaccine mandate.  Currently, only Virginia and 
Washington D.C. have been successful in passing similar legislation. 
Analysis of Issue 
Key Stakeholders 
 There are several key stakeholders in the development of Kentucky House Bill 
358 (2013).  The first are the legislators who sponsored the bill including Representatives 
David Watkins, Tom Burch, Joni L. Jenkins, and Mary Lou Marzian.  Representatives 
Burch, Jenkins, and Marzian are all of the Democratic Party representing Jefferson 
County.  Representative Watkins is also from the Democratic Party representing 
Henderson County.  Representatives Watkins and Marzian are a physician and a nurse, 
respectively.  All four representatives have been previously involved in the sponsorship 
of HPV vaccine related legislation in Kentucky, and all have sponsored previous attempts 
to require the HPV vaccine for school entry in the state.   
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 The Kentucky Medical Association (KMA) is fully supportive of HB 358 (2013).  
One of the public health goals the KMA House of Delegates announced in 2012 was to 
include the HPV vaccine as one of the required vaccines for males and females in 
Kentucky (KMA, 2012).  The group reiterated this stance in a report about HB 358 in the 
May 2013 issue of the KMA Communicator.  The House of Delegates is the legislative 
body of the KMA, and is responsible for developing policy (KMA, 2013b).  The 
American Nurses Association’s (ANA) official stance is that they are supportive of the 
CDC/ACIP recommendations and also of all policies that would improve child and 
adolescent health.  They do recommend that parents have a choice to “opt out” of HPV 
vaccination once they are fully educated about the risks and benefits, and they support 
continued research regarding HPV vaccine efficacy (ANA, 2012).   
 Another key stakeholder in this issue is the pharmaceutical companies that 
manufacture the HPV vaccine.  While it is unclear to what extent the pharmaceutical 
companies were involved in this particular piece of legislation, it is known that they have 
lobbied in other states for similar legislation (Mello, Abiola, & Colgrove, 2012).  
Pharmaceutical companies, especially Merck that manufactures Gardasil (the 
quadrivalent HPV vaccine) stand to gain great financial benefits from the passage of HB 
358 and other comparable legislation that would mandate that adolescents receive the 
HPV vaccine.  
 Finally, The Family Research Council (FRC) and Focus on the Family are two 
conservative Christian groups that oppose HPV vaccine mandates.  Both groups take a 
similar stance in that they support the development of the HPV vaccine and continued 
research regarding its efficacy, but they oppose mandating the vaccine for school entry 
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(Focus on the Family, 2012; Gaul, 2013).  Focus on the Family states that abstinence 
until marriage should be the primary prevention strategy for HPV infection, and that 
decision to vaccinate should be left up to parents.  FRC states that vaccination should be 
choice of the parent after they have discussed the risks and benefits with their healthcare 
provider (Gaul, 2013).      
Individuals affected 
 Kentucky adolescents and their parents would be directly affected by a mandate to 
require HPV vaccination for school entry, particularly those who were not previously 
vaccinated.  While most adolescents and their parents should be educated about and 
offered the vaccine per ACIP recommendations at their 11-12 year old well-child exam, 
the vaccine is not currently required for school attendance.  If HB 358 were passed, 
parents would still be permitted an “opt out” if they did not want their child to receive the 
vaccine.  Although parents would be free to decline vaccination for any reason, a written 
letter of refusal would be required to be kept on file with the child’s immunization 
records.  Additionally, although the Vaccines for Children (VFC) program covers most 
children that are uninsured or underinsured, parents would potentially be responsible for 
out of pocket vaccine expenses. 
 Schools and primary care providers, including family practice providers and 
pediatricians, would also be affected.  Schools would be responsible for instituting 
policies regarding the vaccine mandate and enforcing that students have documentation 
of all required vaccines.  Generally, students cannot attend school without a record of 
required vaccinations.  In the case of the HPV vaccine, the student would either need to 
have received the vaccine, or have an “opt out” letter written by a parent or guardian on 
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file.  It would also be the responsibility of primary care providers to stay up to date on the 
vaccination requirements if new legislation were passed.  This would ensure that they 
could educate parents and adolescents accordingly, and make sure their patient 
populations were up to date on all required vaccines. 
Political Factors 
 According to one study, the pharmaceutical company Merck was heavily involved 
in all areas of legislation regarding mandatory HPV vaccination.  These political 
activities included lobbying, writing proposals, and rallying interest groups (Mello, 
Abiola, & Colgrove, 2012).  California, Indiana, New Hampshire, New York, Texas, and 
Virginia were included in the study.  Kentucky was not included in this particular study, 
and it is unclear how extensively pharmaceutical companies are involved in Kentucky’s 
proposed legislation.  Merck has also provided substantial financial support to Women in 
Government, an organization of female legislators in the U.S. (Colgrove, Abiola, & 
Mello, 2010).  Even if obvious political activities were not present, there could be 
potential contributions to campaign funds by pharmaceutical companies and other actions 
that could affect political outcomes. 
 While HB 358 passed the Kentucky House of Representatives with a vote of 
54/40, this topic appears to have divided the legislators by political party.  Of the 54 ‘yea’ 
votes, only four came from Republicans.  Similarly, only three of the 40 votes to oppose 
the bill were from the Democratic Party.  This is not surprising since the primary 
sponsors of the bill are all from the Democratic Party, and the HPV vaccine mandate has 
been controversial, particularly among conservatives.  However, a previous piece of 
legislation (HR 80, 2012) that urged all eligible males and females in Kentucky to 
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become more knowledgeable about the HPV vaccine was passed nearly unanimously by 
the House in 2012.  This suggests that the majority of legislators are not opposed to the 
HPV vaccine itself, but to the mandate. 
Social Factors 
 While many patients and providers see the vaccine as a great tool for cancer 
prevention, the vaccine has received a stigma among some because it prevents cancer by 
immunizing against a virus that is sexually transmitted.  There has been open debate that 
mandating the vaccine will give adolescents permission to engage in premarital sex or 
sexual promiscuity (Chen, 2012).  Since the vaccine is given to 11 and 12 year olds prior 
to sixth grade entry, parents (and providers) may be uncomfortable engaging in frank 
discussion about sexuality and sexual behavior.  There are also conservative groups that 
advocate delaying sexual activity until after marriage as a way to prevent the spread of 
HPV (Focus on the Family, 2012).     
 A general concern with some parents about vaccines is the potential link to 
adverse health outcomes.  This has lead to a more lenient exemption process in some 
states.  The rate of unvaccinated children in the U.S. rose from 1% in 2006 to 2% in 2011 
(Blank, Caplan & Constable, 2013), and there is currently a movement of parents who 
opt out of vaccination due to safety concerns (Colgrove, 2006).  This general distrust of 
vaccines has carried over for the HPV vaccine, as well.   Additionally, the HPV vaccine 
has been targeted because of the lack of very long-term safety and efficacy studies.   
Economic Issues 
 There are numerous economic issues related to this topic because the HPV 
vaccine is very expensive.  Out of pocket cost for the vaccine averages $130 per 
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injection, or $390 for the vaccine series (American Cancer Society, 2013).  This makes it 
one of the most costly ACIP recommended vaccines.  Additionally, $390 includes just 
the cost of the vaccine series, and does not include any fees that may be charged for 
vaccine administration.  The HPV vaccine is currently covered by the VFC program, 
along with the other ACIP recommended vaccines.  However, not all providers are VFC 
approved.  This means they would have to order the vaccine to have on hand, with the 
potential that it would not be used before its expiration date.  Due to the high cost of the 
vaccine, this is most likely a risk that some providers are not willing to take.         
 According to the fiscal note attached to HB 358 (2013), there would be no fiscal 
impact, as the Commonwealth of Kentucky is not responsible for providing the vaccine 
under the legislation.  This may be misleading, however, because the HPV vaccine is part 
of the VFC program.  VFC uses federal funds to provide ACIP recommended vaccines to 
children younger than 19.  Children that are qualified for VFC are those that are 
Medicaid-eligible, uninsured, underinsured, or American Indian or Alaskan Native 
(CDC, 2012e).  So while Kentucky would not directly be responsible for cost, much of 
Kentucky’s adolescent population qualifies for VFC.  This means that federal spending 
for this program would be greatly increased in a short time span.  If all states were to 
institute similar legislation at the same time, it would be a tremendous strain to the 
system.  Additionally, there would also be potential for increased financial burden to 
private insurers as all eligible children who were previously unvaccinated would be 
receiving the vaccine. 
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Practical Considerations 
 While attempting to improve HPV vaccination rates by requiring the vaccine for 
school entry is a reasonable approach, this is still a controversial topic.  Although 
Virginia and Washington D.C. have been successful in implementing a policy that 
requires the vaccine for adolescent girls with a choice for parental opt out, most states 
have been unsuccessful in instituting HPV vaccine mandates.  There are also many 
questions regarding whether legislators should be involved in deciding what vaccines 
should be required, or whether it should be left up to public health officials (Colgrove, 
Abiola, & Mello, 2010).        
Policy Options 
 In 2013, states chose to approach the need to improve HPV vaccination rates in a 
variety of ways using health policy.  States including Florida, Georgia, and New York 
proposed legislation that would either require that all parents and adolescents receive 
education about the HPV vaccine, or encouraged voluntary vaccination.  Virginia, New 
York, and Kentucky proposed that all adolescents receive the HPV vaccine prior to entry 
into sixth grade (with all states allowing exemptions to vaccination).  There has been 
similar legislation proposed in previous years that would require vaccination of all 
females entering sixth grade.  Instead of proposing vaccine mandates, New Hampshire 
and South Dakota use state funds to offer the vaccine at no cost to any female state 
resident under 18 (NCSL, 2013; Savage, 2007).  Including the states mentioned above, 
there has been proposed legislation to either require HPV vaccination or to require 
education to the public or adolescents regarding HPV vaccination in 42 states since 2006 
(NCSL, 2013). 
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Best Policy Option/Alternative Approaches 
 Because the list of state required vaccines is often based directly on the ACIP 
recommendations, and ACIP recommends the vaccine for all 11-12 year olds, it would 
seem only natural that the HPV vaccine should be added to the list of vaccinations 
required for school entry.  However, as previously discussed, the vaccine has had many 
unique controversies.  Specifically, it is a vaccine that prevents a virus that is spread only 
by sexual contact.  Currently, the ACIP has not provided any recommendations regarding 
HPV vaccine policy or requirements for school entry.  Policy requiring that all 
adolescents and parents of adolescents receive education from their healthcare provider 
regarding the HPV vaccine would be prudent given the low rates of vaccination.  At this 
time, policy requiring a vaccine mandate may be premature due to political, social, and 
economic concerns surrounding this issue.   
Description of Strategies for Moving Forward 
 The CDC already has strategies in place to increase HPV vaccination rates.  The 
Preteen and Teen Vaccine Communication Campaign focuses on education for 
adolescents (ages 9-18), parents of adolescents, and health care providers who treat 
adolescents.  Its focus is to improve vaccination rates for Tdap, meningococcal (MCV4), 
HPV, and influenza vaccines in this age group.  The focus also includes encouraging 
adolescents to get their vaccines on time and/or make up any missed vaccines.  On the 
CDC website, this campaign includes posters, flyers, and fact sheets that can be printed, 
posted and given out as patient education materials.  It also includes information on the 
Healthy People 2020 objectives for all included vaccines (CDC, 2011b). 
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 Moving forward, providers should not only use the CDC provided information to 
educate themselves, but also provide information for their patients with an included 
strong recommendation to get all ACIP suggested vaccines for their age group.  Providers 
should also use sick visits to make up missed vaccines if possible, since adolescents are 
often not seen by their primary care providers frequently.  Additionally, it is essential to 
stress the importance of receiving all three doses of the HPV vaccine prior to sexual 
debut in order to receive adequate protection.  
Potential Unintended Consequences of Recommended Policy 
 Potential inadvertent outcomes include increases in VFC spending, as currently 
41% of vaccines given to children and adolescents in the United States are paid for by 
VFC (Kaiser Family Foundation, 2013).  There is also potential for increased spending 
by private insurers.  Because of the policy language that allows parents to exempt their 
children from vaccination, there is also a possibility that there would be no change in 
vaccination rates despite policy implementation.  Additionally, students would not be 
allowed to attend Kentucky schools without either receiving the vaccine or providing an 
exemption letter, which poses a potential for truancy issues related to the policy. 
Implementation/Enforcement Issues 
 If a policy mandating HPV vaccination is passed in the future, implementation 
will be similar to that of other required vaccines in Kentucky.  Schools will be 
responsible for enforcing that students have immunization records on file with current 
and required vaccinations, or they will not be allowed to attend school.  If the “opt out” 
language stays in the bill, parents would also have the option to have a written letter on 
file with the child’s immunization records if they choose to decline the HPV vaccine.  
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There could be possible implementation issues until all schools and providers are aware 
that an additional vaccine is required.  Another possible issue could occur if many 
unvaccinated adolescents need to receive the vaccine at the same time, and there are not 
enough VFC vaccinations available, as this could lead to potential delays in vaccinations 
or missed doses.  Finally, as with other vaccinations, requirements will differ by state.  
Students transferring to Kentucky schools may be unvaccinated and will have to either 
become vaccinated or present a letter of exemption prior to starting school.  
Conclusion 
 Providers should continue to follow the ACIP recommendations that all 11-12 
year old males and females receive one dose of Tdap, one dose of meningococcal, and 
three doses of HPV vaccine separated by appropriate intervals (CDC, 2013d).  Providers 
should offer patient and parent education coupled with a strong recommendation that all 
eligible adolescents receive the HPV vaccine.  Large scale studies have shown, and 
continue to show, that the vaccine is safe and effective against cervical, orophayngeal, 
and anal HPV infections.  Long-term efficacy studies are currently in progress.  At this 
time, a vaccine mandate may be premature due to social, financial, and political barriers, 
but providers can still work to increase vaccine acceptance and HPV vaccination rates in 
their patient population.   An important recommendation is to reduce missed 
opportunities to vaccinate by considering every visit with adolescent patients as a chance 
to review immunization records and check for missed vaccines/doses.    
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Chapter 4 
Manuscript #3: 
Assessing Providers’ Facilitators and Barriers to Recommending the HPV Vaccine 
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Abstract 
Background:  Human papillomavirus (HPV) vaccines have been shown to be effective 
against HPV types that are linked to cervical, vaginal, vulvar, penile, anal, and 
oropharyngeal cancers. Despite Advisory Committee on Immunization Practices (ACIP) 
recommendations that all 11-12 year old males and females in the U.S. should be 
vaccinated with the three-dose HPV vaccine series, vaccination rates remain low.  In 
2012, only 34.9% of adolescent females and 6.8% of adolescent males completed the 
series.  Efforts to increase vaccination rates are needed, and healthcare providers have 
been shown to be an important part of the solution. 
Purpose:  This investigation was conducted to determine providers’ current practices 
regarding HPV vaccine recommendation, consistency with following ACIP guidelines, 
and perceived facilitators and barriers to recommending the HPV vaccine. 
Methods:   This descriptive study utilized a retrospective chart review of all 11-12 year 
old adolescents presenting to a primary care clinic for a well-child exam between April 
23, 2013 and September 30, 2013. Charts were audited for patient demographics, whether 
HPV vaccination counseling was offered and by whom, patient response 
(accepted/declined/deferred), if the vaccine was initiated, and if it was completed.  
Additionally, an anonymous provider survey was administered via REDCap and a 
provider focus group was conducted to elicit perceived facilitators and barriers to 
recommending the vaccine.  
Results:  Chart audits (N= 60) revealed that 42% of the adolescents initiated the vaccine, 
and only 14% completed the series within the CDC recommended interval.  Review of 
provider documentation revealed that counseling and/or provider recommendation was 
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documented in only 11 of 60 charts.  Barriers to vaccine initiation included 
recommending the vaccine more often to female than male patients, language barriers, 
low medical literacy, time constraints, inconsistent patient follow-up, and patient/parent 
concerns about long-term safety. 
Recommendations:  Based on focus group discussion, suggestions to improve HPV 
vaccination rates included offering a strong provider recommendation for HPV 
vaccination to all adolescent patients, standardizing documentation of HPV vaccine 
recommendation, and using the EMR to improve return rates for second and third vaccine 
dose.  
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Assessing Providers’ Facilitators and Barriers to Recommending the HPV Vaccine 
Introduction 
 Human papillomavirus (HPV) is the most common sexually transmitted infection 
(STI) in the United States with 79 million existing cases in 2008, and 14 million new 
cases annually (CDC, 2013a).  Currently, over $8 billion is spent each year on the 
prevention and treatment of HPV infection in the U.S. (Chesson, Ekwueme, Saraiya, 
Lowry, & Markowitz, 2012), and HPV is the second most costly STI after HIV (CDC, 
2013a).  Infection with certain cancer causing strains of HPV has been linked to the 
development of cervical, vaginal, vulvar, penile, anal, and oropharyngeal cancers (CDC, 
2011a; Markowitz, 2007).  Over 99% of cervical cancers (HHS, 2012), 95% of anal 
cancers (CDC, 2013e), and approximately 70% of newly diagnosed oropharyngeal 
cancers in the U.S. (Herrero et al, 2013) are caused by HPV.  The majority of these 
cancers are caused by oncogenic HPV types 16 or 18 (Herrero et al., 2013; HHS, 2012; 
Palefsky et al., 2011).  Additionally, HPV types 6 and 11 are responsible for over 90% of 
anogenital warts, and are also linked to conjunctival, nasal, oral, and laryngeal warts 
(CDC, 2012a).    
 Currently, two HPV vaccines are approved for use by the United States Food and 
Drug Administration (FDA).  The bivalent (HPV2) vaccine protects against HPV types 
16 and 18; the quadrivalent (HPV4) vaccine protects against types 6, 11, 16, and 18.  
Both vaccines are recommended for use in females, while only the quadrivalent vaccine 
is recommended for use in males.  The Centers for Disease Control and Prevention’s 
(CDC) Advisory Committee on Immunization Practices (ACIP) currently recommends 
routine vaccination of all 11-12 year old females with either the bivalent or quadrivalent 
three-dose vaccine series, and all 11-12 year old males with the quadrivalent vaccine 
 
 
41 
 
series.  Females ages 13-26 and males ages 13-21 (and up to age 26 in special 
populations including men who have sex with men) should receive catch-up vaccination 
(CDC, 2011a; Markowitz, 2007).    
     Despite the ACIP recommendation to vaccinate all adolescents, rates of 
vaccination have remained low.  In 2012, according to data from the National 
Immunization Survey (NIS) Teen, 53.8% of girls ages 13-17 in the United States initiated 
the HPV vaccine and only 33.4% completed the three-dose series (CDC, 2013c).  HPV 
coverage in female adolescents dropped from 2011 to 2012 in the U.S. (CDC, 2013d).  In 
Kentucky, 51.2% of females initiated vaccination in 2012, while 34.9% completed the 
series.  In males ages 13-17 in the U.S., 20.8% initiated vaccination and 6.8% completed 
the series in 2012 (CDC, 2013d).  Healthy People 2020 objectives include increasing 
vaccine coverage amongst adolescents, and more specifically, increasing the number of 
females ages 13-15 who have completed the three-dose HPV vaccine series to 80% 
(HHS, 2013).   
 While the U.S. and Kentucky vaccination rates are similar, there is undeniably a 
need to increase vaccination rates.  Input from providers could provide valuable 
information about barriers to vaccination of children often faced in clinical practice. The 
purpose of this investigation is to 1) determine providers’ current practices related to 
HPV vaccine recommendations and their consistency with following the ACIP guidelines 
and 2) to identify providers’ perceived facilitators and barriers to recommending the HPV 
vaccine.  Provider suggestions to decrease barriers to recommending the HPV vaccine 
and improve vaccination rates are also described. 
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Methods 
 This descriptive study consisted of three parts:  a retrospective chart review 
(phase 1), a provider survey (phase 2), and a provider focus group (phase 3).  All phases 
were conducted by the principal investigator (PI) within the primary care clinic. 
Retrospective Chart Review 
 Objective.  Phase 1 consisted of a retrospective chart review to:  1.) determine the 
rate of HPV vaccination among 11-12 year old adolescents presenting to the clinic for 
well-child exams between April 23, 2013 and September 30, 2013; and 2.) assess whether 
providers at the primary care clinic were recommending and offering the HPV vaccine to 
their adolescent patients according to ACIP guidelines.  Additionally, patient 
demographics, including gender, age, race, and insurance type were recorded. 
 Methods and Design.  This descriptive, retrospective chart review included all 
male and female, 11-12 year old patients that presented to a primary care clinic for their 
well-child exams between April 23, 2013 and September 30, 2013.  After approval from 
the Institutional Review Board (IRB) was received, a patient list was obtained that 
included medical record numbers of all patients meeting inclusion criteria that were 
coded with the ICD-9 for a well-child exam (V20.2).  This list contained a total of 68 
medical record numbers.  A chart audit tool (Appendix A) was used to review the patient 
charts to determine if vaccine counseling was provided and by whom, whether the 
vaccine was offered by the provider, whether the vaccine was accepted/declined/deferred 
by the patient, if the vaccine series was initiated, and if it was completed.  Gender, age at 
time of visit, race, and type of insurance were recorded.  The principal investigator (PI) 
entered the de-identified data into the chart audit tool in Research Electonic Data Capture 
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(REDCap).  REDCap is a secure online data collection tool hosted by the University of 
Kentucky (Harris et al., 2009).  Data was then stored under password protection on the 
PI’s personal mobile electronic device.  
 All male and female patients, ages 11-12, that presented to an outpatient, primary 
care clinic in an urban setting between April 23, 2013 and September 30, 2013 for a well-
child exam (ICD-9 code V20.2) were included in the study.  This timeframe was chosen 
because April 23, 2013 was the date that electronic medical record (EMR) use started in 
this clinic, and this interval was intended capture all adolescents presenting for their well-
child exams prior to entry into sixth grade.  Once the data was analyzed, patients that had 
initiated or completed the HPV vaccine series prior to their well-child exam were 
excluded from the study.  This excluded eight patients, making the final number of 
participants 60. 
Provider Survey 
 Objectives.  The intention of the provider survey was to examine the providers’ 
current practices related to recommending the HPV vaccine, their current knowledge of 
the ACIP recommendations regarding the HPV vaccine, and their perceived facilitators 
and barriers to recommending the vaccine to their adolescent patients.   
 Methods.  An anonymous survey was administered to the providers email address 
using REDCap (Harris et al., 2009) [Appendix B].  The survey was administered to all 
providers (physicians and advanced practice nurses) that practice within the primary care 
clinic where the project took place.  The survey asked providers how often they offer the 
HPV vaccine to both male and female patients, and how often patients accept the vaccine 
when offered.  It also inquired about potential facilitators and barriers to recommending 
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the HPV vaccine that the providers might experience in practice. Finally, it asked a series 
of questions to determine the providers’ knowledge of the ACIP recommendations 
regarding the HPV vaccine. 
Provider Focus Group 
 Objectives.  The focus group was held in order to identify and discuss providers’ 
perceived facilitators and barriers to recommending the HPV vaccine series to their 
adolescent patients.  In addition, a brief presentation was given by the PI that reviewed 
the ACIP recommendations regarding administration of the HPV vaccine, and discussed 
the results of the retrospective chart review.  An open forum was used to provide an 
opportunity for providers to discuss facilitators and barriers to recommending the HPV 
vaccine and to offer suggestions on how to improve related practice within the clinic.  
 Focus Group Procedures/Process.  All providers at the primary care clinic were 
invited via email to attend the focus group, which was held at the clinic during regular 
operating hours.  Informed consent was collected prior to the initiation of the discussion.  
Risks and benefits as well as contact information for the Office of Research Integrity 
(ORI) were discussed prior to commencing the focus group.  The PI gave a brief Power 
Point presentation that discussed background and incidence of HPV infection in the 
United States, current ACIP recommendations for HPV vaccination, and rates of HPV 
vaccination in the U.S. and Kentucky.  The results of the retrospective chart review were 
also presented at this time.  The discussion was informal, and all providers were 
encouraged to ask questions and express opinions and concerns freely during the 
presentation.  At the conclusion of the presentation, providers were asked:  
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 What factors within your practice facilitate the recommendation of the HPV 
vaccine according to ACIP guidelines?   
 What barriers do you experience in your practice that makes recommending the 
HPV vaccine difficult?   
 Do you have any suggestions that would make recommending the HPV vaccine 
easier within your practice? 
Results 
Retrospective Chart Review 
 Patient Demographics.  In the final sample of 60 patients, 25 were female (42%) 
and 35 were male (58%).  The majority of the patients (58%) were African American, 
with 13% white, 12% both Hispanic and biracial, 3% Middle Eastern, 2% Asian, and 2% 
undocumented.  The vast majority of the patients were covered by government insurance 
(85%), with 10% being uninsured and 5% having private insurance.   
 Counseling on HPV vaccine provided during visit.  Of the 60 patient charts 
reviewed, 11 (18%) had documentation of counseling on the HPV vaccine during the 
well-child visit.  Currently there is not a specific place in the clinic’s EMR to document 
any type of counseling, but several providers notated in the discussion section regarding 
HPV vaccine counseling.  However, documentation of counseling was not consistent, and 
was more likely to be documented if the patient or parent declined or deferred 
vaccination. 
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Figure 1:  Describing if HPV vaccine counseling was offered and if so, did patient 
initiate or not initiate vaccination. 
 
 Initiation of the HPV vaccine.    At this primary care clinic during the given 
time frame (April 23, 2013 to September 30, 2013), 25 patients or 42% of the sample, 
received their first dose of the HPV vaccine.  In 2012 in the United States, 53.8% of 
adolescent females and 20.8% of adolescent males initiated the HPV vaccine series.  
Similarly, 51.2% of adolescent females in Kentucky received at least one dose of the 
HPV vaccine in 2012 (CDC, 2013f).  There is not currently data for Kentucky male 
vaccination rates. 
Table 1      
Total Patients Initiating HPV Vaccine by Gender 
 Study total Number initiated Percentage initiated 
Males 35 15 43% 
Females 25 10 40% 
 
60 patients 
11 counseled 
4 initiated 
7 did not initiate 
49 not 
counseled 
21 initiated 
28 did not 
initiate 
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Figure 2.  Clinic HPV Vaccine Initiation Rates compared to 2012 U.S. and Kentucky 
Data 
 
 Second and/or Third Dose of Vaccine Administered on Time.  The CDC 
recommends that the second dose of HPV vaccine be given one to two months after the 
first dose, and the third dose be given six months after the first dose.  According to these 
guidelines, all 25 patients that initiated vaccination would have been eligible for the 
second dose of the vaccine at the time of the chart review.  However, only 32% (8/25 
patients) had completed the second dose of the vaccine.  Additionally, there was at least a 
six month interval since the first dose in seven patients, making them eligible for the third 
vaccine dose.  Only 14% (1/7 patients) of those eligible to receive the third dose of 
vaccine had done so.  Nationally, 33.4% of adolescent females and 6.8% of adolescent 
males completed all three doses of the HPV vaccine in 2012 (CDC, 2013f).  
Provider Survey 
 Two of the four providers that practice at the primary care clinic responded to the 
REDCap (Harris et al., 2009) survey.  One provider responded that they offered the HPV 
vaccine to all (100%) 11-12 year old male and female patients, and that 50-74% of 
females and 25-49% of males initiate vaccination.  The second provider reported offering 
the vaccine to 50-74% of male patients and 75-99% of female patients, with a 50-74% 
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acceptance rate for females and 1-25% acceptance rate for males.  The providers agreed 
facilitators to HPV vaccination within their clinic included the fact that the clinic 
participates in the Vaccines for Children Program (VFC) and that their patient population 
believed in primary prevention.  The barriers included:  patients had long-term safety 
concerns about the vaccine, patients were unlikely to return for the second and third dose, 
and that the vaccine was not required for school.  Other facilitators and barriers discussed 
in the provider survey are presented in Table 2.  The providers reported that they were 
both aware of the current ACIP recommendations.  Both respondents answered questions 
correctly regarding their knowledge of the ACIP recommendations for both males and 
females.    
Table 2 
Provider Facilitators/Barriers Identified in REDCap Survey, N=2 
 Provider 1 Provider 2 
Facilitators   
Practice participates in VFC X X 
Clinic has reminders within the EHR   
Adequate time available to educate patients about HPV  X 
Pts have good understanding of HPV risks  X 
Pts believe in primary prevention X X 
Pts aware of VFC  X 
Pts have good family/peer support to vaccinate  X 
Barriers   
Vaccine not stocked/low availability   
Practice not adequately reimbursed X  
Not time to discuss HPV/vaccine X  
Provider long-term safety concerns   
Provider uncomfortable discussing HPV/vaccine   
Provider does not agree with ACIP recommendation   
Patient long-term safety concerns X X 
Patients unlikely to return for doses 2 & 3 X X 
Vaccine not required for school X X 
Patients concerned about pain   
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Provider Focus Group  
 Focus group data was recorded and transcribed by the PI and briefly reviewed 
with the providers at the conclusion of the focus group.  The comments were then 
grouped by theme.  No identifying information was recorded during the focus group in 
order to keep the discussion confidential.  Three of the four providers that practice at the 
clinic participated in the focus group.  There was both physician and advanced practice 
nurse representation.   
 Perceived facilitators to recommending the HPV vaccine. 
 Use of the electronic medical record (EMR).  The implementation of the 
electronic medical record, which occurred April 23, 2013 in this clinic, was mentioned as 
both a facilitator and a barrier during the focus group.  The providers perceived the 
uncomplicated access to the immunization record as a facilitator as it provides immediate 
access to the patient’s vaccination status.  They agreed that having access to vaccination 
status is important for reducing missed doses.  One provider also noted that there were 
several options that he/she had been using within the EMR including having the nurse 
chart “patient refusal” under the vaccination tab anytime that a vaccine was declined, and 
entering a request for a nurse visit when the patient received the initial vaccine dose so 
that the front desk was prompted to make return visits for second and third dose upon 
check-out.  The other participating providers were not aware of these options within the 
EMR prior to the focus group discussion.   
 Perceived Barriers to Recommending the HPV Vaccine. 
 Inconsistencies between male and female patients.  One provider noted that 
he/she inconsistently offered the vaccine to male patients and was much more likely to 
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offer the vaccine to female patients.  The provider noted that since the recommendation 
to vaccinate males was more recent, it had not become habit to offer it to every patient.  
The other providers stated that they offered the vaccine to both males and females 
equally, but they felt that parents of male patients were less likely to be aware of the 
ACIP recommendations for males and they often required additional counseling 
regarding the vaccine and were more likely to decline or defer vaccination. 
 Patient/parent knowledge and beliefs.  The themes that emerged related to 
patient and parent knowledge and beliefs included low medical literacy of patients and 
their parents, language barriers, and the impression that because the vaccine is not 
mandatory that it is not necessary.  The providers pointed out that they felt that their 
particular patient population had lower medical literacy, especially concerning the HPV 
vaccine.  They care for a fairly large number of international patients, and frequently the 
11-12 year old well-child exam is the first time the patient and parents have heard of the 
vaccine.  Because of this, vaccination is frequently deferred at that visit.  The lower 
education level of the parents and frequent use of medical interpreters during visits make 
the discussion about the vaccine even more difficult.  One provider stated that it “would 
be less complicated if the HPV vaccine was mandated for school entry, because patients 
and parents would be more likely to accept vaccination.”  
 Uncertainty about documentation in EMR.  While some aspects of the electronic 
medical record have been helpful in vaccinating patients, implementation of the system 
has also added barriers.  Currently in the EMR, there is not a specific place to document 
patient counseling.  Two of the providers said that they attempt to remember to document 
counseling as a free text under the “discussion” tab, but that it is difficult to remember 
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since they are not prompted.  One provider stated that his/her documentation of 
counseling was much more consistent prior to the implementation of the electronic 
system.  
 Time.  At this clinic, providers have approximately 15-20 minutes to spend with 
patients during well-child exams.  The providers acknowledged that patients often used 
their well-child exams as problem visits and for medication refills, leaving very little time 
for patient counseling regarding the HPV vaccine and other topics.  While patients are 
given an information sheet about the vaccine by the nurse when they enter the exam 
room, the providers felt there is not always adequate time for them to review that 
information with patients and parents.   
 Difficulty with patient follow-up.  The providers all noted that follow-up for 
second and third doses of the HPV vaccine were problematic.  They reported that it was 
difficult to get patients to return to the clinic for vaccination.  They cited the following 
reasons for not returning:  lack of patient transportation to clinic for visits, high no-show 
rates within the clinic, and insufficient clinic staffing so that it was difficult to send out 
patient reminders prior to visits. 
 Provider Suggestions for Improvement.  The providers agreed that they needed 
to have a discussion about a routine place to document vaccine counseling.  Additionally, 
they agreed that when the HPV vaccine was administered to an adolescent patient, they 
needed to enter a nurse visit to prompt the front desk to make appointments for the 
second and third doses at clinic check-out.  They also concluded that the best approach to 
recommending and offering the vaccine included presenting the HPV vaccine as a 
potential preventive measure against cancer. 
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Discussion 
 The ACIP recommends that adolescents receive the HPV vaccine at age 11-12 so 
that all doses can be completed prior to the initiation of sexual activity.  This provides the 
best protection against HPV infection (Markowitz et al., 2007).  The retrospective chart 
review showed that while this primary care clinic had HPV vaccine initiation rates for 
male adolescents above the U.S. average, the rate for female adolescents was well below 
both the U.S. and Kentucky averages.  Additionally, provider recommendation for 
vaccination was not consistently documented during well-child exams, and patient 
follow-up for second and third vaccine doses was inconsistent. 
This clinic is not unique with its low vaccination rates.  The President’s Cancer 
Panel (PCP) issued a report in February 2014 to discuss urgent actions needed to increase 
vaccination rates in the U.S.  One of the goals detailed in this report is to “reduce missed 
opportunities to recommend and administer HPV vaccine” (PCP, 2014, p. ii).  To meet 
this goal, healthcare providers should strongly recommend the HPV vaccine to all male 
and female patients that are eligible for vaccination.  Additionally, they should use 
electronic medical records to assist in reducing missed opportunities (PCP, 2014).  
According to the 2012 NIS-teen, 84% of girls that had not received the HPV vaccine had 
record of an appointment where they received a vaccine but not the HPV vaccine (CDC, 
2012a).  
The provider survey and focus group results indicated that the providers at this 
clinic find that their participation in VFC, their patients’ beliefs in primary prevention, 
and the fact that the vaccination record is easily accessed in the EMR facilitated 
recommending and initiating the HPV vaccine.  However, the main obstacles reported 
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were inconsistencies in provider recommendation between male and female patients, 
patient concerns about long term safety, difficulty with patient follow-up for second and 
third doses, lack of a vaccine mandate for school entry, low medical literacy of parents 
and patients, inadequate time to discuss vaccine with patients, and uncertainty of proper 
documenation within the EMR. 
 The barriers expressed during the provider focus group are not unique, and similar 
obstacles have been described in other studies.  Systematic reviews have found that a 
knowledge gap among patients regarding HPV (Holman et al., 2014), parental beliefs 
about the HPV vaccine (Holman et al., 2014), vaccine cost (Holman et al., 2014; 
Rambout, Tashkandi, Hopkins, & Tricco, 2014), and patient concerns about vaccine 
safety (Rambout et al., 2014) were some of the leading obstacles to vaccine acceptance.  
Conversely, patients reported that lack of strong provider recommendation was a barrier.  
A strong provider recommendation was linked to increased vaccine acceptance and 
initiation (Holman et al., 2014; Rambout et al., 2014).  Social pressures and perceived 
vaccine benefit also increased likelihood that patients would initiate the vaccine series 
(Rambout et al, 2014).   
 Finally, while this clinic had better vaccine initiation rates for males than the U.S. 
average in 2012, there is still room for improvement.  During the focus group one 
provider acknowledged that they were less likely to recommend the HPV vaccine to their 
male adolescent patients due to forgetfulness.  This provider noted that since the ACIP 
recommendation was only released for males in 2011, it had not become routine practice 
for them.  Research has indicated that providers should focus on educating parents about 
the etiology of HPV infection and the vaccine’s role in preventing cancer in males when 
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discussing the HPV vaccine with the parents of male adolescents (Thomas, Strickland, 
DiClemente, & Higgings, 2014).  Additionally, parents may not be aware that vaccination 
of all 11-12 year old males is an ACIP recommendation since it was released in 2011.   
Limitations 
 There were several limitations to this project including the small sample size 
(N=60).  However, since this sample included all 11-12 year old patients that were seen 
for a well-child exam during the specified timeframe, it is a good indicator of how many 
adolescent patients are typically seen annually prior to sixth grade entry at this clinic.  
Another limitation is the start date of the retrospective chart review (April 23, 2013).  
This date was chosen because it was the date that the clinic began using electronic health 
records exclusively.  This could be a potential disadvantage because there was a learning 
curve with using the EMR, and initially the clinicians were not familiar with charting 
within the system.  A third limitation is that only two providers completed the REDCap 
survey.  Finally, there are potential limitations with using focus groups to gather 
information.  There is a possibility that the providers would not feel comfortable sharing 
their true thoughts and patient practices with other providers present.     
Implications for Practice 
 Suggestions to improve practice include improving standardizing documentation.  
Providers should come to a consensus about a consistent place to document vaccine 
counseling.  Additionally, they should enter a nurse visit for every patient that initiates 
the HPV vaccine.  This will prompt the front desk to make the patient return visits for 
second and third vaccine doses at patient check-out.  In addition, recommendations from 
the provider survey and focus group include being consistent about offering the HPV 
 
 
55 
 
vaccine to all eligible patients.  If possible posters in the patient rooms and prompts 
within the EMR to offer the vaccine could serve as a good reminder.  Providers should 
offer educational materials regarding the HPV vaccine in a variety of languages for their 
international patients.  Finally, while it may be costly for clinic staff to send patient 
reminders, it may be possible for automated reminders to be sent to patients via email or 
text.  Some research has indicated that text reminders have potential to increase HPV 
vaccine completion rates among adolescents (Matheson et al., 2013). 
 The providers within this clinic are knowledgeable about the HPV vaccine and are 
enthusiastic about offering it to their patients.  Minor adjustments in practices and 
modifying the EMR system to simplify practice will help promote increased vaccine 
acceptance and initiation.  While there is not currently a Healthy People 2020 goal for 
adolescent males, they should strive to increase the number of males that initiate and 
complete vaccination and increase the number of female adolescents that completed the 
three-dose series to meet the Healthy People 2020 goal of 80%.  They should focus on 
increasing provider recommendation of the HPV vaccine, standardizing documentation of 
vaccine recommendation, and improving return rates for second and third vaccine dose to 
improve their HPV vaccine completion rates. 
 
 
 
 
 
 
 
 
56 
 
 
 
 
 
 
 
 
Chapter 5 
Capstone Report Conclusion 
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Conclusion 
 Although implementation of routine vaccination of adolescents with the three-
dose HPV vaccine has proven to be safe and effective in reducing infection with vaccine 
HPV types, rates of vaccination in the U.S. are suboptimal.  Healthcare policy aimed at 
mandating HPV vaccines for adolescents prior to sixth grade entry have been largely 
unsuccessful.  Low vaccination rates have triggered both the U.S. Department of Health 
and Human Services (HHS) and the President’s Cancer Panel (PCP) to take action.  One 
of the Healthy People 2020 goals is to increase the number of females ages 13 to 15 that 
have completed the three-dose HPV vaccine series to 80% (HHS, 2012).  Additionally, 
the President’s Cancer Panel (PCP) recommends that any barriers that prevent providers 
from strongly recommending the HPV vaccine be removed.  The PCP also calls for the 
development of a Healthy People 2020 goal for HPV vaccine completion in male 
adolescents (PCP, 2014). 
 A quality improvement project with the goal of assessing providers’ facilitators 
and barriers to recommending the HPV vaccine to their adolescent patients was 
conducted in an urban primary care clinic.  The results showed that vaccination rates 
within the clinic were inadequate, and that documentation of vaccine recommendation 
was not consistent.  Providers within the clinic identified barriers to recommending the 
HPV vaccine to their patients including lack of time during patient visits, a tendency to 
recommend the vaccine more often to females than males, language barriers between 
providers and patients, low medical literacy of patients and their parents, low likelihood 
that patients would return for follow-up vaccine doses, the fact that the vaccine is not 
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currently mandated for sixth grade entry in Kentucky, and lack of a standardized place to 
document HPV vaccine recommendation. 
 Primary care providers can play an integral part in increasing HPV vaccine rates 
among adolescents.  They should continue to strongly recommend the HPV vaccine to all 
eligible patients according to ACIP recommendations.  Additionally, it is important for 
providers to be aware of facilitators and barriers in practice and how they affect HPV 
vaccine recommendation.  Finally, providers should stay educated regarding ACIP 
recommendations, Healthy People 2020 goals, and healthcare policy related to the HPV 
vaccine so they can offer well-informed guidance to their patients.  The completion of 
this project is a step toward that goal.  The primary care clinic has been given a summary 
of findings to assist in the development of interventions to improve HPV vaccination 
rates.   
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Appendix A 
 
Assessing Providers’ Facilitators and Barriers to Recommending the HPV Vaccine 
  Chart Audit Tool 
 
Study number:_______________ 
Gender:_____________________ 
Age:________________________ 
Race:_______________________ 
Insurance:___________________ 
 
 
 
At the patient’s 11/12 year old well-child visit, were the following documented: 
 
 
Information Yes No Comments 
Was counseling on 
the HPV vaccine 
provided? 
 
 
By: ___ CMA 
      ____NP/MD 
  
Was the HPV 
vaccine offered? 
 
   
Patient’s response 
if vaccine was 
offered 
__ Accepted 
__ Deferred 
__ Declined 
  
Was the HPV 
vaccine series 
initiated? 
   
Was the vaccine 
series initiated or 
completed prior to 
this visit? 
   
 
Doses given (Y/N)? #1_________  #2__________  #3___________ 
           On-time?    Y/N   Y/N  Y/N 
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Appendix B 
Assessing Providers’ Facilitators and Barriers to Recommending the HPV Vaccine:  Survey/Questionnaire  
Please answer the following questions by selecting the answer that best represents your experience as a 
provider: 
1.  How often do you offer the HPV vaccine during routine well-child exams for 11-12 year old 
FEMALES? 
 100%  25-49% 
 75-99%  0-25% 
 50-74% 
 
2.    How often do you offer the HPV vaccine during routine well-child exams for 11-12 year old MALES? 
 100%  25-49% 
 75-99%  0-25% 
 50-74% 
 
3.  When offered, what percentage of your FEMALE patients accept HPV vaccination: 
 100%  25-49% 
 75-99%  0-25% 
 50-74% 
 
4.  When offered, what percentage of your MALE patients accept HPV vaccination: 
 100%  25-49% 
 75-99%  0-25% 
 50-74% 
 
Which of these factors affect your decision to recommend the HPV vaccine in your current practice?  
Please select all that apply: 
Practice Facilitators Practice Barriers 
 My practice participates in the 
Vaccines for Children (VFC) program. 
 The HPV vaccine is not stocked or there is low 
availability in my practice. 
 My clinic has reminders within the 
AEHR for HPV vaccination. 
 My practice is not adequately reimbursed for 
HPV vaccine administration. 
 My clinic uses a form during well-
child exams that prompts for CDC 
recommended vaccinations. 
 I do not have time to discuss HPV vaccination 
during patient visits. 
 I have time to educate my patients 
about HPV and the vaccine. 
Other: 
Other:  
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Which of these factors affect your decision to recommend the HPV vaccine in your current practice?  
Please select all that apply: 
Provider Facilitators Provider Barriers 
 I strongly recommend the HPV 
vaccine to all eligible patients. 
 I have concerns about the long-term safety of 
the HPV vaccine. 
 I have completed continuing 
education regarding HPV and/or the 
HPV vaccine. 
 I feel uncomfortable discussing a vaccine for a 
sexually transmitted infection with my patients 
and/or their parents. 
 I am aware of the CDC/ACIP 
recommendations for HPV 
vaccination. 
 I do not agree with the CDC/ACIP 
recommendations for HPV vaccination. 
Other:  
 
Other: 
  
Patient Facilitators Patient Barriers 
 My patients have a good 
understanding of the risks of HPV 
infection. 
 My patients are unaware of the risks of HPV 
infection. 
 My patients/their parents believe 
that they are at risk for HPV. 
 My patients think the cost of the HPV vaccine 
is too high. 
 My patients have a belief in primary 
prevention. 
 My patients are worried about the long-term 
safety of the HPV vaccine. 
 My patients are aware of the 
Vaccines for Children (VFC) program 
and its coverage. 
 My patients are unlikely to return for the 2
nd
 
and 3
rd
 dose of the vaccine series. 
 My patients have positive 
peer/family support regarding HPV 
vaccination. 
 My patients are unlikely to get the vaccine 
because it is not required for school entry. 
Other:   My patients are concerned about the pain 
associated with the HPV vaccine. 
Other: 
 
 
Please answer the following questions about the CDC/ACIP recommendations for HPV vaccination to the 
best of your knowledge: 
8.  What is the recommended interval for HPV vaccination? 
a.  0, 3, and 6 months   
b.  0, 1-2, and 6 months 
c.  0, 3, 6, and 9 months 
d.  0, 6, and 9 months 
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9.  What is the ideal age of vaccination for males and females? 
a.  ages 11-12, can be given as early as 9 
b.  ages 13-15, can be given as early as 11 
c.  ages 9-13, can be given as early as 9 
d.  ages 15-18, can be given as early as 9 
10. What are the recommendations for catch-up vaccination for males and females? 
a.  Catch-up for unvaccinated men and women ages 13-18. 
b.  Catch-up for unvaccinated men and women ages 13-21. 
c.  Catch-up for unvaccinated men ages 13-21 (and up to 26 for special populations), catch-up for women 
13-26. 
d.  Catch-up for unvaccinated men ages 15-21 (and up to 26 for special populations), catch-up for women 
15-26. 
 
 
Comments: Please feel free to share any comments or ideas you have related to the HPV vaccine 
recommendations for 11-12 year olds in your clinic…   
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